The Future is Now:
Evolving Standards of Care in MIBC & la/mUC

TumorBoardTuesday MIBC Convo

This activity is jointly provided by Partners for Advancing Clinical Education (Partners) and Bonum CE in partnership with TumorBoardTuesday.

This program has been supported by independent educational grants from Astellas and Pfizer.

Program Overview

Current standard of care for patients with muscle-invasive bladder cancer (MIBC) is radical cystectomy with neoadjuvant systemic platinum-based chemotherapy, however, systemic chemotherapy is associated with significant toxicity. Several phase 3 trials are investigating the combined use of ICIs and ADCs in the treatment of MIBC in hopes to improve safety and efficacy compared to the cytotoxic sledgehammer of chemotherapy.

This CME-certified, social media-based activities will provide learners with information regarding best practices and data regarding these new and evolving classes of therapies, as well as information regarding treatment safety profiles and appropriate management of adverse events.

This activity, the first in the series, is a X/Twitter-based Clinical Conversation hosted by TumorBoardTuesday focused on neoadjuvant and perioperative treatment of MIBC.

Faculty

Michael J Pishvaian, MD, PhD (TumorBoardTuesday Founder)
Associate Professor
Department of Oncology
Director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center
Sibley Memorial Hospital
John Hopkins School of Medicine
Washington, District of Columbia

Yüksel Ürün, MD (guest faculty)
Professor of Medicine
Department of Medical Oncology
Ankara University School of Medicine
Ankara, Turkey

Emre Yekedüz, MD (guest faculty)
Research Fellow
Department of Genitourinary Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Target Audience

This program is intended for medical, surgical, radiation oncologists, urologists, fellows, trainees, oncology advance practice providers, oncology nurses, and oncology pharmacists caring for patients with mUC.

Learning Objectives

After completing this activity series, learners should be better able to analyze the role of antibody-drug conjugates and their potential to address unmet needs for additional therapy options in earlier stages of urothelial carcinoma.

Disclosure of Relevant Financial Relationships

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

 

  • Michael J Pishvaian, MD, PhD
    Consultant, Advisor: Astra Zeneca, Merus, Merck, Moderna, Serna Bio, Revolution Medicine, Theriva Biologic
    Contractor: Astellas, Novartis, Pfizer
    Steering Committee: Astellas, RenovoRx
    Contracted Research: Actuate, Amgen, Arcus Bio, Astellas, Boerhinger Ingelheim, Elevation Oncology, Ideaya, Lilly, MEI Pharma, Merck, Novartis, Parabalis, Pfizer, Recursion Pharma, Repare Tx, Tesaro
    Individual publicly traded stocks and stock options: Perthera
    Other: RenovoRx, Astellas, Merus, Revolution Medicine

    Yüksel Ürün, MD
    Advisory boards: Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Eczacıbaşı, Gen ilaç, GSK, Janssen, Merck, MSD, Nobel, Novartis, Pfizer, Roche
    Travel, Honoraria or consultation fees: Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Eczacıbaşı, Gen ilaç, GSK, Janssen, Merck, MSD, Nobel, Novartis, Pfizer, Roche

    Emre Yekedüz,MD
    Nothing to disclose

Joint Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bonum CE. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

Release date: July 29, 2025
Expiration date: July 29, 2026
Estimated time to complete activity: 1 hour